Home
Search
Search Results
Previously Searched
3140 results found
Expand All
Apply All
3140 results found

Startups

Human Health

How Committees Work
Employees of member companies may be involved in committees as much or as little as they want to be. Committee members participate in committee calls to speak up about issues that are important to them, or simply network with peers. Here is a framework in which BIO can help support your objectives:
Read More

Join Committees - Have a Voice
All BIO members have a voice, and our policy initiatives reflect the diversity of our membership. BIO members are able to participate in committees to provide a unified voice on policy and advocacy issues in the biotech community.
Read More

BIO's Comments on Advisory Committee on Immunization Practices (ACIP) - December 2025
Letters, Testimony & Comments  •  December 4, 2025
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in advance of the December 4-5, 2025 meeting. BIO encourages the reinstatement of several long-standing practices that have historically supported ACIP’s application of high-caliber science and transparent evidence-based decision making to safeguard Americans’ ability to protect against deadly infectious disease and avoid unintended disruptions to vaccine supply and patient access.BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 35 other nations. BIO membership includes vaccine developers and manufacturers who have worked closely with the public health community to support policies that help ensure access to innovation and life-saving vaccines for all individuals.For decades, the U.S. has been a global leader in scientific rigor and health innovation in vaccines, exemplified by policy developed through a transparent and predictable process. The Committee’s recommendations have earned trust because they have been consistently informed by structured evaluations that used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system and the Evidence to Recommendation (EtR) processes. Continuous consistency and predictability in vaccine guidance from ACIP allows the U.S. to accelerate the delivery of vaccines to those wanting and needing them and to support the ongoing development of new vaccines.The longstanding ACIP process provides a model of integrity and transparency. Its success lies in structured reviews of the full body of evidence related to a vaccine conducted over multiple public meetings supported by…
Read More

Reauthorizing the PRV
Policy
prv

BIO Statement on the Retirement of Richard Pazdur from US FDA
Press Release  •  December 2, 2025
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA.“Dr. Pazdur has dedicated decades of his career to public service and the needs of patients. He exemplifies the type of expert and steady leadership that has made the United States the home to the world’s leading medical breakthroughs. Dr. Pazdur’s departure raises serious concerns about the repeated turnover in key leadership occurring at the FDA.  We need organizational strength and stability at the Agency. This constant turmoil is undermining America's leadership in biotechnology, creating unprecedented regulatory instability and unpredictability, and risks ceding this critical sector to China. As BIO has long upheld - it is imperative that we retain and recruit scientific expertise and strong leadership of the highest caliber at our health agencies and that the standards that are the hallmark of these health institutions are upheld and advanced. We are at a tipping point. It is time to right this ship.”###About the Biotechnology Innovation Organization (BIO)BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.
Read More

New Report Highlights State and Regional Strategies Powering U.S. Biotech
Press Release  •  December 2, 2025
WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report on best practices in bioscience economic development initiatives: The U.S. Bioscience Industry: A Powerful Engine for State Economies.The report details the diverse strategies states, cities, and municipalities are using to strengthen the bioscience ecosystem in their communities and support America's global leadership in biotechnology."This report underscores how deeply biotechnology is woven into our nation's fabric and serves as a roadmap for how states can help maintain America’s global biotechnology leadership," said John F. Crowley, President and CEO of BIO. "It shows how smart investments in biomanufacturing, research, and workforce development don't just bring effective medicines to patients, they also foster economic vitality across the country."The report examines public policy initiatives across all 50 states and Puerto Rico, highlights standout programs, and identifies national trends, including:R&D Incentives: Thirty-nine states and Puerto Rico now offer research and development tax credits, many refundable, to help early-stage bioscience companies access capital. Thirty-two states and Puerto Rico support SBIR/STTR matching grants for companies in their regions. In the coming decade, the bioscience market is expected to expand rapidly -- with forecasts predicting it will reach over $5 trillion by 2034.Jobs & Investment Boosts: States are expanding job creation and capital investment grants to attract and retain bioscience employers that inject our economy with good-paying jobs. In the U.S. alone, the bioscience industry's total economic impact (as measured by overall output) exceeded $3.2 trillion in 2023, supporting a large number of direct and indirect jobs.Manufacturing Tax Relief: Forty states and Puerto Rico are offering sales and use tax…
Read More

Council of State Bioscience Associations
Council for State Biotechnology Associations (CSBA)
.accordion h3 { background: #eee; transition: 0.3s; -moz-transition: 0.3s; -webkit-transition: 0.3s; padding: 15px 30px 15px 12px; font-size: 16px; line-height: 18px; cursor: pointer; position: relative; margin: 0 0 4px; } Image The Council of State Bioscience Associations (CSBA) is a confederation of state-based, non-profit trade organizations each governed by its own board of directors. The common mission of CSBA members is to promote public understanding and to advocate for public policies that support the responsible development of the bioscience industry. These groups are recognized by BIO as affiliate organizations in their respective states.  The contents of this listing may not be reproduced or used in any form without prior written permission from BIO.Bryan BrownExecutive DirectorPO BOX 20065Charleston, WV 25362(304) 529-0803www.biowv.org
Read More

BIO Statement on House Passage of Mikaela Naylon Give Kids a Chance Act
Press Release  •  December 1, 2025
WASHINGTON, D.C. – The Biotechnology Innovation Organization (BIO) released the following statement on today’s passage of the Mikaela Naylon Give Kids a Chance Act in the House of Representatives.“The unanimous House passage of the Mikaela Naylon Give Kids a Chance Act is a victory for children and families living with rare diseases. We applaud the House for their commitment to this life-saving measure, and to a key part of the bill – the reauthorization of the Pediatric Priority Review Voucher program.This commonsense legislation brings hope to the families of the sickest children by renewing a program, which, for more than a decade, has helped incentivize the development of treatments for rare pediatric diseases at no cost to taxpayers. We urge the Senate to get this essential legislation across the finish line and reauthorize the PPRV program.”###About the Biotechnology Innovation Organization (BIO)BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.
Read More